Jounce Therapeutics Inc

Jounce Therapeutics — Technical Presentation (June 2018)

18 slides from Jounce Therapeutics's technical presentation, Jun 4, 2018

  1. Slide 1: ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-2011 +/- nivolumab

    ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-2011 +/- nivolumab (nivo) in patients with advanced cancers Timothy A. Yap1, Howard A. Burris2, Shivaani Kummar3, Gerald S. Falchook4, Russell K. Pachynski5, Patricia LoRusso6, Scott S. Tykodi7, Geoffrey T. Gibney8, J

  2. Slide 2: Why Choose ICOS as a Target?

    Why Choose ICOS as a Target? • ICOS: Inducible CO-Stimulator of T cells • Expression on T cells associated with favorable outcome with ipilimumab • Preclinical data show functional importance of host ICOS • Upregulated by variety of agents – ideal combination target Ipilimumab-treated melanoma patie

  3. Slide 3: JTX-2011: Preclinical Rationale for ICOS Agonist IgG1 Antibody

    JTX-2011: Preclinical Rationale for ICOS Agonist IgG1 Antibody Shifting the balance of T cells towards antitumor activity APC NK JTX-2011 cell 1st signal ICOS ICOS TCR TCR ICOS ↑↑IFN-γ ↑ IFN-γ X T regulatory cell “Non-Primed” “Primed” T effector cell T effector cell Activation and Selective reductio

  4. Slide 4: ICONIC Phase and Objectives

    ICONIC Phase 1 and 2 Objectives Phase 1 Phase 2 Primary: JTX-2011 alone and in combination with nivo Primary: JTX-2011 alone and in combination with nivo • Safety and tolerability • Preliminary efficacy by RECIST 1.1 (CT scans q9w)* • MTD and RP2D • Confirm safety and tolerability • Confirm MTD and

  5. Slide 5: ICONIC Study Design

    ICONIC Study Design Phase 1 Phase 2 All solid tumors, no enrichment for ICOS expression Enriched for pts with high ICOS expression NSCLC* HNSCC* JTX-2011 Dose Escalation JTX-2011 0.003-1.0 mg/kg IV q3w 0.3 mg/kg IV q3w Any solid tumor type PK/PD Expansions Phase 2 Gastric* Triggered Additional tumor

  6. Slide 6: ICONIC Patient Demographics

    ICONIC Patient Demographics JTX-2011 JTX-2011 + nivo Parameter Phase 1 Phase 2 Phase 1 Phase 2 n 40 29 31 87 Median age, yrs (Range) 63 (24, 78) 67 (31, 81) 56 (29, 80) 62 (37, 85) ECOG 0/1, n (%)/n (%) 8 (20%) / 32 (80%) 2 (7%) / 27 (93%) 8 (26%) / 22 (71%)* 25 (29%) / 60 (71%)* Tumor types 8-TNBC,

  7. Slide 7: ICONIC Phase Characteristics

    ICONIC Phase 2 Characteristics Tumor type HNSCC NSCLC TNBC Gastric Other Solid Tumors JTX-2011 JTX-2011 JTX-2011 JTX-2011 JTX-2011 JTX-2011 JTX-2011 JTX-2011 JTX-2011 + nivo + nivo + nivo + nivo + nivo n* 4 23 5 13 19 8 29 12 3 Prior therapy for n=4 n=22 n=5 n=12 n=19 n=8 n=29 n=11 n=3 metastatic di

  8. Slide 8: JTX-2011 is Well Tolerated Alone and Combined with nivo

    JTX-2011 is Well Tolerated Alone and Combined with nivo JTX-2011 JTX-2011 + nivo Phase 1: all doses (n=40) n (%) Phase 2 (n=29) n (%) Phase 1 all doses (n=31) n (%) Phase 2 (n=87) n (%) Related AEs* All TEAEs Grade 3/4 All TEAEs Grade 3/4 All TEAEs Grade 3/4 All TEAEs Grade 3/4 Any related TEAE 23 (

  9. Slide 9: JTX-2011 Pharmacokinetics and Pharmacodynamics

    JTX-2011 Pharmacokinetics and Pharmacodynamics Phase 1 Phase 2 • RP2D 0.3 mg/kg mono and combo based on: • RP2D 0.3 mg/kg mono and combo confirmed: • Safety • Sustained Target Engagement beyond Cycle 1 • Sustained Target Engagement in • No significant change in IFN-gamma after first peripheral blood

  10. Slide 10: JTX-2011 Monotherapy: Clinical Activity

    JTX-2011 Monotherapy: Clinical Activity Phase 1 (n=40*) Phase 2 (n=27*) • Durable SD • Ongoing RECIST PR in 1/8 gastric 140 • Endometrial 7+ mths, CRPC 6+ mths • Gastric 8.5+ mths 120 • Disease Control Rate = 25% (10) • Disease Control Rate = 19% (5) 100 • 75% discontinuation ≤ C3, 15% in C1 • 78% d

  11. Slide 11: JTX-2011 + nivo: Clinical Activity

    JTX-2011 + nivo: Clinical Activity Phase 1 (n=31*) Phase 2 (n=75*) • Ongoing RECIST PR in 1/4 gastric • Ongoing RECIST PRs and/or SD • Gastric 11+ mths (JTX-2011 0.1 mg/kg) • Gastric, TNBC, NSCLC • Disease Control Rate = 29% (9) • Disease Control Rate = 32% (24) • 58% discontinuation ≤ C3, 10% in C1

  12. Slide 12: JTX-2011 + nivo: Ongoing Disease Control in Gastric, TNBC and NSCLC

    JTX-2011 + nivo: Ongoing Disease Control in Gastric, TNBC and NSCLC 80 Gastric cancer 80 TNBC n= 28 Tumor reductions= 29% (8) n= 17 Tumor reductions= 12% 60 ORR= 4% (1) 60 (2) 40 DCR= 36% (10) 40 ORR= 6% (1) 20 20 DCR= 18% (3) 0 0 -20 -20 -40 -40 Change frombaseline (%) Change frombaseline (%) -60 -

  13. Slide 13: ICOS Expression in ICONIC Patient Tumor Samples

    ICOS Expression in ICONIC Patient Tumor Samples All evaluable matched archival and • Preliminary data suggests relationship between fresh tumor biopsies n (%) archival and fresh pre-Tx biopsy ICOS scores may vary: (Phase 1 and Phase 2) • May reflect the inducible nature of ICOS # matched pairs archi

  14. Slide 14: ICOS Expression in ICONIC Patient Peripheral Blood Samples

    ICOS Expression in ICONIC Patient Peripheral Blood Samples Tumor Reductions Associated with Emergence of ICOShi CD4+ T cell Population Emergence of ICOShi CD4+ T cell population JTX-2011 ICOS • Observed in 7/7 subjects with target PR* ICOS • Not observed in 10/10 subjects with PD* ↑IFN-γ ↑IFN-γ “Pri

  15. Slide 15: JTX-2011 Monotherapy RECIST PR in Gastric Cancer

    JTX-2011 Monotherapy RECIST PR in Gastric Cancer Tumor reduction associated with emergence of ICOShi T cell population • 51yo female diagnosed with advanced gastric cancer June 2016 • 3 prior lines of therapy, IO naïve • JTX-2011 therapy began May 2017; Durable RECIST PR 8.5+ mths (ongoing) Emergenc

  16. Slide 16: JTX-2011 + nivo RECIST PR in Gastric Cancer

    JTX-2011+ nivo RECIST PR in Gastric Cancer hi Tumor reduction associated with emergence of ICOS T cell population Baseline (12.6cm) 5/18/2017 • 43yo female diagnosed with MSS gastric adenocarcinoma in Dec 2013 • 6 prior lines of therapy, IO naive • JTX-2011 therapy (0.1mg/kg) + nivo (240mg q3w) bega

  17. Slide 17: Conclusions

    Conclusions • Safety and tolerability demonstrated in heavily pre-treated patients - JTX-2011 0.3 mg/kg well tolerated as monotherapy and with nivo 240 mg q3w • RECIST partial responses and stable disease in advanced cancers - Gastric cancer- mono and combo PRs - TNBC- combo PR - NSCLC- combo stable

  18. Slide 18: The ICONIC investigators would like to thank

    The ICONIC investigators would like to thank: All patients and their families The clinical study teams and participating centers Jounce Therapeutics Timothy A. Yap MD, PhD 18

Jounce Therapeutics — Technical Presentation (June 2018) on 6ix